Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Survey of Canadian urology programs: Which aspects of the Canadian Residency Matching Service (CaRMS) application are the most important?

Nguyen DD, Lee JY, Domes T, El-Sherbiny M, Andonian S, Franc-Guimond J, Letendre J, Perrotte P, Bhojani N.

Can Urol Assoc J. 2020 Jan 20. doi: 10.5489/cuaj.6191. [Epub ahead of print]

PMID:
31977301
2.

The Association of Faculties of Medicine of Canada's electives diversification policy: Potential drawbacks and benefits for medical students applying to urology.

Nguyen DD, Lee JY, Couture F, Richard PO, Fahmy N, Perrotte P, Domes T, Bhojani N.

Can Urol Assoc J. 2019 Dec;13(12):427-429. doi: 10.5489/cuaj.6000. Epub 2019 Apr 26. No abstract available.

3.

Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes.

Mistretta FA, Cyr SJ, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, Briganti A, Shariat SF, Perrotte P, Saad F, de Cobelli O, Karakiewicz PI.

Clin Oncol (R Coll Radiol). 2019 Nov 6. pii: S0936-6555(19)30448-0. doi: 10.1016/j.clon.2019.10.001. [Epub ahead of print]

PMID:
31706712
4.

Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.

Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lavallee LT, Karakiewicz PI.

Minerva Urol Nefrol. 2019 Sep 4. doi: 10.23736/S0393-2249.19.03496-9. [Epub ahead of print]

PMID:
31487976
5.

Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):e1026-e1035. doi: 10.1016/j.clgc.2019.06.003. Epub 2019 Jun 13.

PMID:
31378580
6.

Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality.

Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI.

World J Urol. 2019 Jul 11. doi: 10.1007/s00345-019-02869-6. [Epub ahead of print]

PMID:
31297629
7.

Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates.

Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Tilki D, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI.

Urol Oncol. 2019 Sep;37(9):578.e11-578.e19. doi: 10.1016/j.urolonc.2019.05.024. Epub 2019 Jul 8.

PMID:
31296420
8.

Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy.

Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, Shariat SF, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug;17(4):e793-e801. doi: 10.1016/j.clgc.2019.04.015. Epub 2019 Apr 30.

PMID:
31182339
9.

The AFMC electives diversification policy: Potential drawbacks and benefits for medical students applying to urology.

Nguyen DD, Lee JY, Couture F, Richard PO, Fahmy N, Perrotte P, Domes T, Bhojani N.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.6000. [Epub ahead of print] No abstract available.

PMID:
31039115
10.

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.

El Ghorayeb N, Rondeau G, Latour M, Cohade C, Olney H, Lacroix A, Perrotte P, Sabourin A, Mazzuco TL, Bourdeau I.

Medicine (Baltimore). 2016 Mar;95(13):e3180. doi: 10.1097/MD.0000000000003180. Erratum in: Medicine (Baltimore). 2016 Sep 09;95(36):e29d2.

11.

Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes.

Trudeau V, Gandaglia G, Shiffmann J, Popa I, Shariat SF, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

Can Urol Assoc J. 2014 Sep;8(9-10):E695-701. doi: 10.5489/cuaj.2051.

12.

Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study.

Larouche A, Becker A, Schiffmann J, Roghmann F, Gandaglia G, Hanna N, Tian Z, Perrotte P, Schlomm T, Graefen M, Ahyai S, Trinh QD, Karakiewicz PI, Sun M.

Can Urol Assoc J. 2014 May;8(5-6):E419-24. doi: 10.5489/cuaj.1790.

13.

The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.

Gandaglia G, Karakiewicz PI, Abdollah F, Becker A, Roghmann F, Sammon JD, Kim SP, Perrotte P, Briganti A, Montorsi F, Trinh QD, Sun M.

Eur J Surg Oncol. 2014 Dec;40(12):1706-15. doi: 10.1016/j.ejso.2014.05.001. Epub 2014 May 22.

PMID:
24915856
14.

Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Sun M, Trinh QD, Perrotte P, Karakiewicz PI.

Eur Urol. 2014 May;65(5):1014-5. doi: 10.1016/j.eururo.2013.12.042. No abstract available.

PMID:
24646500
15.

Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy.

Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, Shariat SF, Perrotte P, Chun FK, Graefen M, Karakiewicz PI.

Can Urol Assoc J. 2014 Jan-Feb;8(1-2):E75-80. doi: 10.5489/cuaj.749.

16.

Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample.

Becker A, Bianchi M, Hansen J, Tian Z, Shariat SF, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

World J Urol. 2014 Dec;32(6):1511-21. doi: 10.1007/s00345-014-1256-y. Epub 2014 Feb 11.

PMID:
24515596
17.

Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments.

Gandaglia G, Abdollah F, Hu J, Kim S, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M.

J Endourol. 2014 Jul;28(7):784-91. doi: 10.1089/end.2013.0774. Epub 2014 Mar 24.

PMID:
24499306
18.

Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.

Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F.

BJU Int. 2014 Dec;114(6b):E62-E69. doi: 10.1111/bju.12645. Epub 2014 Jul 15.

19.

The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period.

Gandaglia G, Trinh QD, Hu JC, Schiffmann J, Becker A, Roghmann F, Popa I, Tian Z, Perrotte P, Montorsi F, Briganti A, Karakiewicz PI, Sun M, Abdollah F.

Eur J Surg Oncol. 2014 Sep;40(9):1080-6. doi: 10.1016/j.ejso.2013.12.016. Epub 2014 Jan 2.

PMID:
24411705
20.

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.

Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M.

Crit Rev Oncol Hematol. 2014 Apr;90(1):49-57. doi: 10.1016/j.critrevonc.2013.12.003. Epub 2013 Dec 12. Review.

PMID:
24411587
21.

Local tumor destruction in renal cell carcinoma--an inpatient population-based study.

Trudeau V, Becker A, Roghmann F, Shariat SF, Kluth LA, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

Urol Oncol. 2014 Jan;32(1):54.e1-7. doi: 10.1016/j.urolonc.2013.08.030.

PMID:
24360664
22.

Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M.

Prostate. 2014 Feb;74(2):210-6. doi: 10.1002/pros.22742. Epub 2013 Oct 16.

PMID:
24132735
23.

Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis.

Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2014 May;113(5):733-40. doi: 10.1111/bju.12288. Epub 2013 Sep 5.

24.

Robot-assisted vs. laparoscopic partial nephrectomy: utilization rates and perioperative outcomes.

Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, Bianchi M, Hansen J, Perrotte P, Peabody JO, Rogers CG, Shariat SF, Menon M, Trinh QD.

Int Braz J Urol. 2013 May-Jun;39(3):377-86. doi: 10.1590/S1677-5538.IBJU.2013.03.11.

25.

Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma.

Meskawi M, Becker A, Bianchi M, Trinh QD, Roghmann F, Tian Z, Graefen M, Perrotte P, Karakiewicz PI, Sun M.

Int J Urol. 2014 Feb;21(2):122-8. doi: 10.1111/iju.12204. Epub 2013 Jul 2.

26.

In-hospital mortality and failure-to-rescue rates after radical cystectomy.

Trinh VQ, Trinh QD, Tian Z, Hu JC, Shariat SF, Perrotte P, Karakiewicz PI, Sun M.

BJU Int. 2013 Jul;112(2):E20-7. doi: 10.1111/bju.12214.

27.

Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.

Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):E283-9. doi: 10.1111/bju.12115.

28.

Sociodemographic disparities in the treatment of small renal masses.

Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, Shariat SF, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):E274-82. doi: 10.1111/bju.12111.

29.

An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.

Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):1184-90. doi: 10.1111/bju.12084. Epub 2013 Apr 12.

30.

An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma.

Sun M, Shariat SF, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI.

Ther Adv Urol. 2013 Apr;5(2):121-8. doi: 10.1177/1756287212466128.

31.

Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.

Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

BJU Int. 2014 Jan;113(1):36-42. doi: 10.1111/j.1464-410X.2012.11693.x. Epub 2013 Mar 12.

32.

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

Cancer Epidemiol. 2013 Jun;37(3):219-25. doi: 10.1016/j.canep.2013.02.002. Epub 2013 Feb 26.

PMID:
23485480
33.

Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: a population-based evaluation.

Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, Shariat SF, Perrotte P, Karakiewicz PI, Sun M.

Int J Urol. 2013 Nov;20(11):1064-71. doi: 10.1111/iju.12110. Epub 2013 Feb 19.

34.

Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?

Sun M, Ravi P, Karakiewicz PI, Sukumar S, Sammon J, Bianchi M, Shariat SF, Jeong W, Ghani KR, Hansen J, Friedman A, Perrotte P, Peabody JO, Menon M, Trinh QD.

Urol Oncol. 2014 Jan;32(1):27.e7-13. doi: 10.1016/j.urolonc.2012.09.012. Epub 2013 Feb 10.

PMID:
23403162
35.

Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients.

Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Mod Pathol. 2013 Aug;26(8):1144-9. doi: 10.1038/modpathol.2012.230. Epub 2013 Feb 1. Erratum in: Mod Pathol. 2013 Aug;26(8):1152.

36.

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI.

Cancer Treat Rev. 2013 Jun;39(4):388-401. doi: 10.1016/j.ctrv.2012.12.006. Epub 2013 Jan 12.

PMID:
23317510
37.

Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy.

Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.

Ann Surg Oncol. 2013 Jun;20(6):2096-102. doi: 10.1245/s10434-012-2806-4. Epub 2012 Dec 23.

PMID:
23263779
38.

A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis.

Thuret R, Sun M, Budaus L, Abdollah F, Liberman D, Shariat SF, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.

Cancer Causes Control. 2013 Jan;24(1):71-9. doi: 10.1007/s10552-012-0091-y. Epub 2012 Oct 30.

PMID:
23109172
39.

Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study.

Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, Shariat SF, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.

Can Urol Assoc J. 2012 Aug;6(4):245-50. doi: 10.5489/cuaj.12032.

40.

Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach.

Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, Bianchi M, Peabody JO, Shariat SF, Perrotte P, Hu JC, Menon M, Trinh QD.

J Urol. 2013 Apr;189(4):1289-94. doi: 10.1016/j.juro.2012.10.028. Epub 2012 Oct 22.

PMID:
23085052
41.

Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines.

Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2013 Apr;20(4):405-10. doi: 10.1111/j.1442-2042.2012.03171.x. Epub 2012 Oct 8.

42.

Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.

Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Int J Urol. 2013 Apr;20(4):372-80. doi: 10.1111/j.1442-2042.2012.03170.x. Epub 2012 Oct 8.

43.

In-hospital mortality and failure to rescue after cytoreductive nephrectomy.

Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M.

Eur Urol. 2013 Jun;63(6):1107-14. doi: 10.1016/j.eururo.2012.08.069. Epub 2012 Sep 7.

PMID:
22981674
44.

The effect of gender on nephrectomy perioperative outcomes: a national survey.

Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, Shariat SF, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.

Can J Urol. 2012 Aug;19(4):6337-44.

PMID:
22892256
45.

Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy.

Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI.

Urology. 2012 Aug;80(2):347-53. doi: 10.1016/j.urology.2012.04.043. Epub 2012 Jun 13.

PMID:
22698478
46.

Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?

Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

J Sex Med. 2012 Nov;9(11):2961-9. doi: 10.1111/j.1743-6109.2012.02806.x. Epub 2012 Jun 6.

PMID:
22672479
47.

Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.

Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

BJU Int. 2013 Jan;111(1):67-73. doi: 10.1111/j.1464-410X.2012.11254.x. Epub 2012 May 22.

48.

Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.

Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

J Urol. 2012 Jul;188(1):73-83. doi: 10.1016/j.juro.2012.03.005. Epub 2012 May 12.

PMID:
22578732
49.

A review of integrated staging systems for renal cell carcinoma.

Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Eur Urol. 2012 Aug;62(2):303-14. doi: 10.1016/j.eururo.2012.04.049. Epub 2012 May 3. Review.

PMID:
22575911
50.

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.

Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2012 Sep;19(9):836-44. doi: 10.1111/j.1442-2042.2012.03052.x. Epub 2012 May 10.

Supplemental Content

Loading ...
Support Center